Aurinia Pharmaceuticals
AUPH
78 hedge funds and large institutions have $194M invested in Aurinia Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
28% more capital invested
Capital invested by funds: $151M → $194M (+$42.4M)
28% more funds holding
Funds holding: 61 → 78 (+17)
13% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $3.46M
6.51% more ownership
Funds ownership: 26.04% → 32.55% (+6.5%)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$27.9M |
| 2 |
O
OrbiMed
New York
|
+$20.9M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$2.42M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$2.14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.29M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$2.72M |
| 3 |
Goldman Sachs
New York
|
-$1.88M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.5M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$453K |
AUPH Hedge Fund Activity: Q1 2019 in Review
78 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2019, worth a combined $194M — up 28% from $151M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AUPH positions and 5 closed out — a net gain of 17 holders — while 18 added to existing stakes and 19 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $27.9M. The largest seller was Fidelity Investments, cutting an estimated $3.29M.
- 78 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2019, up from 61 in Q4 2018.
- Funds reported $194M of Aurinia Pharmaceuticals stock for Q1 2019, up 28% quarter-over-quarter.
- 22 funds opened new Aurinia Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +17 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2019 was Consonance Capital Management, an estimated $27.9M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2019 was Fidelity Investments, an estimated $3.29M sold.
Based on aggregated 13F filings for Q1 2019.